This company seems to have been delisted
Reason: Merged with Viewpoint Molecular
Last recorded trade on: April 21, 2023
Source: https://isoray.com/2023/02/isoray-completes-merger-with-viewpoint-molecular-targeting-to-advance-new-treatment-paradigm-in-targeted-precision-oncology-medicine/
Reason: Merged with Viewpoint Molecular
Last recorded trade on: April 21, 2023
Source: https://isoray.com/2023/02/isoray-completes-merger-with-viewpoint-molecular-targeting-to-advance-new-treatment-paradigm-in-targeted-precision-oncology-medicine/
Isoray
ISR
HK$2.98
Share price
0.00%
Change (1 day)
35.66%
Change (1 year)
Categories
Revenue for Isoray (ISR)
Revenue in 2022 (TTM): HK$70.24 Million
According to Isoray
's latest financial reports the company's current revenue (TTM 
) is HK$69.52 Million. In 2021 the company made a revenue of HK$83.35 Million an increase over the revenue in the year 2020 that were of HK$76.76 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Isoray from 2002 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | HK$70.24 M | -15.73% |
| 2021 | HK$83.35 M | 8.59% |
| 2020 | HK$76.76 M | 17.77% |
| 2019 | HK$65.17 M | 25.31% |
| 2018 | HK$52.01 M | 23.31% |
| 2017 | HK$42.18 M | 22.85% |
| 2016 | HK$34.33 M | -10.49% |
| 2015 | HK$38.35 M | 17.99% |
| 2014 | HK$32.51 M | -9.42% |
| 2013 | HK$35.89 M | -0.64% |
| 2012 | HK$36.12 M | -8.96% |
| 2011 | HK$39.68 M | -0.23% |
| 2010 | HK$39.77 M | -3.56% |
| 2009 | HK$41.24 M | -16.49% |
| 2008 | HK$49.38 M | -8.37% |
| 2007 | HK$53.89 M | 85.45% |
| 2006 | HK$29.06 M | |
| 2004 | N/A | |
| 2003 | N/A | |
| 2002 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | HK$3.51 B | 4,953.42% | 🇺🇸 USA |
 | HK$2.19 B | 3,059.59% | 🇺🇸 USA |
 | HK$31.31 B | 44,942.94% | 🇺🇸 USA |
 | HK$355.08 B | 510,650.53% | 🇺🇸 USA |